Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 5/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 2/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411128 | 1.00 | ULK1 (0.36) | ULK1PIM1ROCK1TLR9TLR8 | |
| SCHEMBL5411129 | 1.00 | ULK1 (0.36) | ULK1PIM1ROCK1TLR9TLR8 | |
| SCHEMBL5419458 | 1.00 | ULK1 (0.36) | ULK1PIM1ROCK1TLR9TLR8 | |
| SCHEMBL5411125 | 1.00 | ULK1 (0.36) | ULK1PIM1ROCK1TLR9TLR8 | |
| SCHEMBL5409734 | 0.85 | FEN1 (0.34) | TLR9TLR8TLR7CDK2FLT3 | |
| SCHEMBL5425478 | 0.85 | FEN1 (0.34) | TLR9TLR8TLR7CDK2FLT3 | |
| SCHEMBL5409728 | 0.85 | FEN1 (0.34) | TLR9TLR8TLR7CDK2FLT3 | |
| SCHEMBL5409206 | 0.84 | ULK1 (0.38) | ULK1PIM1ROCK1CHEK1KCNH2 | |
| SCHEMBL5412699 | 0.84 | ULK1 (0.38) | ULK1PIM1ROCK1CHEK1KCNH2 | |
| SCHEMBL5409209 | 0.84 | ULK1 (0.38) | ULK1PIM1ROCK1CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ULK1 1090/4885PIM1 760/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.